A practical reference on heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-07 and is reviewed periodically as new material appears.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
=== Temporal lobe === Functions of the temporal lobe are related to many of the deficits observed in individuals with ASDs, such as receptive language, social cognition, joint attention, action observation, and empathy. The temporal lobe also contains the superior temporal sulcus and the fusiform face area, which may mediate facial processing. It has been argued that dysfunction in the superior temporal sulcus underlies the social deficits that characterize autism. Compared to neurotypical individuals, one study found that individuals with high-functioning autism had reduced activity in the fusiform face area when viewing pictures of faces.
=== Recreational === The perceived effects are said to resemble those of 3-MMC, users report reduced effects and a shorter duration in comparison. Effects include stimulation, euphoria, and increased confidence, libido, and sociability. It can be administered orally or through nasal insufflation. As with other stimulant drugs, rectal and intravenous administration is also possible. The acute effects of 3-CMC last 1 to 4 hours, depending on the administration method. After effects, like difficulty sleeping, can last 3 to 12 hours longer.
== About == LECO develops and manufactures elemental measurement and molecular Time-of-flight mass spectrometry instrumentation, following ISO 9000 standards. The LECO trademark is an acronym of the original name, Laboratory Equipment Company. One of LECO's early products was a combustion analyzer invented by Krasl in 1957 that used crucibles invented by his employee Eugene Bennet. LECO carries out research in many fields of analytical chemistry including protein measurement in foods, sulfur in coal emissions, glow discharge emission in metals, multi-dimensional gas chromatograph mass spectrometry, environmental monitoring, air quality, Metabolomics, and diverse medical and pharmaceutical applications. LECO has been a manufacturer and distributor of metallographic equipment since the 1970s, and makes ceramic products for the foundry industry. LECO Corporation has sales subsidiaries worldwide. On June 8, 1977, Robert J. Warren (1933-2022), husband of Elizabeth D. Schultz and son-in-law of Carl Schultz, and family, have become the sole owners of the company, acquiring outstanding stocks which had become the property of the George J. Krasl Trust following George Krasl's death on August 5, 1976. Bob Warren was hired by LECO in 1968 and became its president in 1975. LECO became a worldwide supplier of instruments and metallographic equipment under Warren's management, and one of southwestern Michigan's larger employers. In 2012 LECO began a partnership with the Joint Mass Spectrometry Centre. Warren was succeeded as CEO by his sons upon his retirement in 2016.
=== Detection === Modafinil is considered a stimulant doping agent and as such is prohibited by World Anti-Doping Agency in sports competitions. Modafinil enantiomers can be separately quantified in biological samples.
Sources: en.wikipedia.org
Communication delays during the crisis led to the establishment of the Moscow–Washington hotline to allow reliable, direct communications between the two nuclear powers. By the late 1960s, the number of ICBMs and warheads was so high on both sides that it was believed that both the United States and the Soviet Union were capable of completely destroying the infrastructure and a large proportion of the population of the other country. Thus, by some western game theorists, a balance of power system known as mutually assured destruction (or MAD) came into being. It was thought that no full-scale exchange between the powers would result in an outright winner, with at best one side emerging the pyrrhic victor. Thus both sides were deterred from risking the initiation of a direct confrontation, instead being forced to engage in lower-intensity proxy wars. During this decade the People's Republic of China began to build subterranean infrastructure such as the Underground Project 131 following the Sino-Soviet split. One drawback of the MAD doctrine was the possibility of a nuclear war occurring without either side intentionally striking first. Early Warning Systems (EWS) were notoriously error-prone. For example, on 78 occasions in 1979 alone, a "missile display conference" was called to evaluate detections that were "potentially threatening to the North American continent". Some of these were trivial errors and were spotted quickly, but several went to more serious levels.
== External links == CRBN protein, human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: Q96SW2 (Protein cereblon) at the PDBe-KB.
==== Imaging ==== Ultrasound of the thyroid may be used to reveal whether structures are solid or filled with fluid, helping to differentiate between nodules and goitres and cysts. It may also help differentiate between malignant and benign lesions. When further imaging is required, a radiolabelled iodine-123 or technetium-99 uptake scan may take place. This can determine the size and shape of lesions, reveal whether nodules or goitres are metabolically active, and reveal and monitor sites of thyroid disease or cancer deposits outside the thyroid. A fine needle aspiration of a sample of thyroid tissue may be taken in order to evaluate a lesion seen on ultrasound which is then sent for histopathology and cytology. Computed tomography of the thyroid plays an important role in the evaluation of thyroid cancer. CT scans often incidentally find thyroid abnormalities, and thereby practically becomes the first investigation modality.
In the process, he found that a precipitation of thorium A (polonium-216) and thorium B (lead-212) also contained a short-lived "element", which he named thorium C (which was later identified as polonium-212). Hahn was unable to separate it, and concluded that it had a very short half-life (it is about 300 ns). He also identified radioactinium (thorium-227) and radium D (later identified as lead-210). Rutherford remarked that: "Hahn has a special nose for discovering new elements."
=== Granulation === Granulation tissue is the perfused, fibrous connective tissue that replaces a fibrin clot in healing wounds. It typically grows from the base of a wound and is able to fill wounds of almost any size as it heals. HA is abundant in granulation tissue matrix. A variety of cell functions that are essential for tissue repair may attribute to this HA-rich network. These functions include facilitation of cell migration into the provisional wound matrix, cell proliferation, and organization of the granulation tissue matrix. Initiation of inflammation is crucial for the formation of granulation tissue; therefore, the pro-inflammatory role of HA as discussed above also contributes to this stage of wound healing.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.